B7-H1/PD-L1/CD274 Antibody

• Catalog Number: orb1806318
• Category: Antibodies
• Description: Anti-B7-H1 / PD-L1 / CD274 Reference Antibody is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hulambda. It has a predicted MW of 145.5 kDa.
• Target: B7-H1 / PD-L1 / CD274
• Clonality: Monoclonal
• Conjugation: Unconjugated
• Reactivity: Canine, Human, Monkey, Mouse, Rabbit, Rat
• Concentration: Batch dependent
• Buffer/Preservatives: 100 mM Proline/Acetic acid 20mM Arginine pH 5.0
• Purity: >95%
• Purification: Protein A
• UniProt ID: Q9NZQ7
• MW: 150 kDa
• Tested applications: ELISA, FA, FACS, In vivo
• Expression System: CHO
• Endotoxins: <0.001 EU/ug
• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Note: For research use only
• Expiration Date: 12 months from date of receipt.

Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (avelumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

The purity of Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (avelumab)is more than 98.22% ;determined by SEC-HPLC.

Immobilized human PD L1 FC at 2 μg/mL can bind Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (avelumab);EC50=0.03725μg/mL.

Avelumab inhibited the tumor growth of MC38 on hLAG3 mice. The result showed significant anti-tumor effects; with an tumor inhibition rate (TGI) of 32.6% at 1 mpk at D28.